What is the dose of aniracetam?

Strengths aniracetam is sold in
FormStrengthWhere it appears
Oral-suspension granule sachet1500 mgItalian product text1
Film-coated tablet750 mgItalian product text1
Capsule200 mgTian's bioequivalence trial in healthy Chinese men2

For adults, the Italian product text for Ampamet, written for attention and memory disorders of the elderly of degenerative or vascular origin, gives a total of 1.500 mg a day in 1-2 administrations: one sachet of granules, or one 750 mg tablet in the morning and one in the evening.1

Strengths aniracetam is sold in

The table is set at the top of the page

A 2021 laboratory analysis of 10 supplement products, not a human trial, measured 0.5 ± 0.0 mg to 502 ± 0.8 mg of aniracetam per recommended serving and found 75% (9/12) of declared drug quantities inaccurate; its authors give 200–750 mg as the typical pharmacologic dose.3

What the product text says about dose

The Italian text for Ampamet, copied by an aggregator from the AIFA text, is written for attention and memory disorders of the elderly of degenerative or vascular origin, and gives adults 1.500 mg a day in 1-2 administrations.1 It says to halve the dose in severe renal insufficiency (creatinine clearance under 10 mL/min), and that the product must not be used in the paediatric population.1

The same aggregator page states the medicine is no longer in the AIFA authorised-medicines database and that the text is outdated.1

How the powder and tablets are taken

The Italian text says the sachet contents are taken after mixing them in half a glass of water, and the tablets are swallowed whole with a sip of water.1

The sachet instruction gives no volume in mL, and the evidence gives no mg/mL concentration, so no syringe mark can be worked.

What the trials used

TrialDose and schedulePeopleLength
Saletu 1980Single oral doses of placebo, 250 mg, 500 mg and 1000 mg, with 2000 mg piracetam as reference410 geriatric subjectsSingle doses at weekly intervals, crossover
Sourander 19871 g daily, versus placebo, double-blind5Forty-four patients with senile dementia of the Alzheimer type3 months
Somnier 19901 g daily, crossover with placebo644 subjects with solvent-related chronic psychosyndrome3 months per treatment period
Senin 1991Dose not given in the record; double-blind, randomized, versus placebo7One hundred and nine elderly patients with mild to moderate cognitive impairment, probable dementia of the Alzheimer type6 months
Canonico 19911500 mg/day by mouth, versus placebo860 patients (mean age 69.9 +/- 10.3 years) with slight-moderate brain pathology primary or secondary to vascular formsTests at baseline and after two and four months
Endo 1997200 mg by mouth, pharmacokinetics compared with young healthy volunteers9Six female hospitalized patients with cerebrovascular disease (mean age 84.5 years)Metabolites peaked at 2 h and returned to basal level by 6 h
Tian 2008Single oral 400 mg dose (2 x 200 mg capsules), fasting, two formulations2Twenty healthy Chinese male volunteersTwo periods, 3-day washout
NCT07852130 (registry entry)100, 200 or 300 mg/day by mouth, given pre-test, versus an inert matched preparation; the registry calls this 5 to 15 times below published human dosing regimens10Seventy healthy adults aged 18-35: 25 on placebo, approximately nine per active compoundSeven assessments over six months
Xu trialDose set by age; both groups had aniracetam, one also Huoxue Tongqiao Decoction1180 elderly patients with post-stroke cognitive impairmentNot stated

In Saletu's single-dose crossover study of 10 geriatric subjects, dose-efficacy curves suggested 1000 mg as the most effective compound of the study, and the authors report a lack of side effects.4 The placebo-controlled trials report different results: in Sourander's, cognitive tests improved in both groups, clinical evaluation found no difference in efficacy, and treatment was interrupted for confusion in four people on aniracetam and one on placebo;5 Somnier's found aniracetam ineffective, with 1 of 19 test measures favouring aniracetam and another test favouring placebo;6 Senin's found a significant difference from placebo by the end of the study;7 and Canonico's found significant improvement at both checks, with no significant change on placebo.8

Cycles, timing and stepping

The evidence gathered gives no cycling, stepping or titration schedule for aniracetam. It says the effect shows after 60 days and is clearer after 4 months of therapy.1 It says that if restlessness, anxiety, evening agitation or insomnia appear, it is advisable to move the second dose to early afternoon, or to take a single dose of 1.500 mg in the morning.1

Storage

The Italian text says the medicine needs no special storage condition and is stable for three years in intact packaging.1

Frequently asked questions

Is aniracetam approved in the US?

A DailyMed search for aniracetam returned no labels, and the evidence gathered establishes no US or EU-central approval.

Is aniracetam approved anywhere else?

The Italian text gives 20 August 1993 as the first authorisation of Ampamet in Italy and 20 August 2008 as the latest renewal.1 The supplement analysis describes aniracetam as a drug approved for use to treat dementia in several countries including Italy, Argentina and China.3

What do Milligram users log for aniracetam?

No logged share of people is available for aniracetam doses, so only sourced figures are reported.

References

  1. AIFA text via Torrinomedica (aggregator copy). Ampamet - Aniracetam: Scheda Tecnica e Prescrivibilità. 2020. torrinomedica.it
  2. PubMed. Pharmacokinetics and bioequivalence study of aniracetam after single-dose administration in healthy Chinese male volunteers. 2008. pubmed.ncbi.nlm.nih.gov
  3. PMC. Five Unapproved Drugs Found in Cognitive Enhancement Supplements. 2021. pmc.ncbi.nlm.nih.gov
  4. PubMed. Quantitative EEG and psychometric analyses in assessing CNS-activity of Ro 13-5057--a cerebral insufficiency improver. 1980. pubmed.ncbi.nlm.nih.gov
  5. PubMed. Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent. 1987. pubmed.ncbi.nlm.nih.gov
  6. PubMed. Aniracetam tested in chronic psychosyndrome after long-term exposure to organic solvents. A randomized, double-blind, placebo-controlled cross-over study with neuropsychological tests. 1990. pubmed.ncbi.nlm.nih.gov
  7. PubMed. Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study. 1991. pubmed.ncbi.nlm.nih.gov
  8. PubMed. [Efficacy and tolerance of aniracetam in elderly patients with primary or secondary mental deterioration]. 1991. pubmed.ncbi.nlm.nih.gov
  9. PubMed. Pharmacokinetic study of aniracetam in elderly patients with cerebrovascular disease. 1997. pubmed.ncbi.nlm.nih.gov
  10. ClinicalTrials.gov. NCT07852130: Reliability of Standardized IQ Testing Under Modafinil, Racetam-Class Compounds, Sleep Restriction and Daily Activity. 2026. clinicaltrials.gov
  11. PMC. Efficacy of Huoxue Tongqiao Decoction combined with aniracetam in treating post-stroke cognitive impairment in elderly patients with ischemic stroke and its effects on serum levels of superoxide dismutase, glutathione peroxidase and nitric oxide. 2026. pmc.ncbi.nlm.nih.gov